BioCentury | Jul 13, 2019
Product Development

Why Merck is in infectious disease for the long haul

...gaining access to its vaccine technology for cancer and infectious disease. Merck also has Sivextro tedizolid phosphate...
...HABP) and ventilator-acquired bacterial pneumonia (VABP). Data posted to ClinicalTrials.gov on June 29 showed that Sivextro...
...endpoint of non-inferiority to linezolid on all-cause mortality (28.1% vs. 26.4%; 95% CI: -8.2, 4.7). Sivextro...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Apr 6, 2015
Finance

Q is for quiet

...melanoma Ph III data April Merck & Co. Inc. (NYSE:MRK)/Dong-A Pharmaceutical Co. Ltd. (KSE:000640) Sivextro tedizolid phosphate...
BioCentury | Feb 9, 2015
Clinical News

Sivextro tedizolid phosphate regulatory update

...EMA’s CHMP recommended approval of oral and IV Sivextro tedizolid from Merck to treat acute bacterial...
...bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) (see BioCentury, June 30, 2014). Merck gained rights to Sivextro...
...Germany Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Sivextro tedizolid phosphate (TR-701) (formerly torezolid phosphate, DA-7218...
BioCentury | Jan 24, 2015
Company News

CHMP recommends Sivextro for ABSSSI

...EMA's CHMP recommended marketing authorization of oral and IV Sivextro tedizolid from Merck & Co. Inc...
...in adults. CHMP said the authorization would include a pharmacovigilance plan. Merck obtained rights to Sivextro...
...bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) (see BioCentury Extra, June 20, 2014) . Cubist gained Sivextro...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...complicated urinary tract infection (cUTI) U.S. Cubist Pharmaceuticals Inc. (NASDAQ:CBST) (B)/Dong-A Pharmaceutical Co. Ltd. (KSE:000640) Sivextro...
...date 2/22/15 Cubist Pharmaceuticals Inc. (NASDAQ:CBST) (A)/Dong-A Pharmaceutical Co. Ltd. (KSE:000640) Oral and IV Sivextro tedizolid phosphate...
BioCentury | Dec 15, 2014
Finance

Uphill road for Cubist CVRs

...million and $5 for sales over $300 million. The Trius CVR is worth $1 if Sivextro...
...$2. Cubist has faced an uphill battle convincing hospitals of the value of Dificid and Sivextro...
...for every 50 patients treated. Meanwhile, Cubist recorded $2.5 million in net product revenues of Sivextro...
BioCentury | Nov 24, 2014
Company News

Cubist, Omnicare sales and marketing update

...to Cubist’s Sivextro tedizolid. The AccessSivextro program will provide patients with a starter dose of Sivextro...
BioCentury | Oct 23, 2014
Cover Story

Diagnosing resistance

...products include Dalvance dalbavancin from Durata Therapeutics Inc. and Gruppo Angelini ; Sivextro tedizolid phosphate ( TR-701...
BioCentury | Oct 7, 2014
Top Story

Actavis raises stakes in ABSSSI race

...about $114 million via a CVR worth up to $2 a share. That deal included Sivextro...
Items per page:
1 - 10 of 69